Burning Rock Biotech
Burning Rock Biotech's revenue rose 4.6% to CN¥540 million in fiscal 2025. Its operating margin was −10.2%, up from −69.3% a year earlier. Free cash flow was −CN¥34 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Burning Rock Biotech does
Burning Rock Biotech is a cancer diagnostics company in China. It uses next-generation sequencing, or NGS, a way of reading many genes at once, to test tumor tissue and blood samples. Doctors use its tests to choose a treatment for a cancer patient. It also sells tests that look for traces of cancer left after surgery, and it is developing blood tests meant to find several cancers early.
It sells its tests in two ways. Hospitals across China send samples to its central laboratory, which runs the tests and issues reports. It also helps hospitals set up their own laboratories, installs the equipment and trains staff, and then sells them reagent kits, the chemicals used to run the tests, on a recurring basis. At the end of 2025 it worked with 94 hospitals in 43 cities this way, and it says it is now putting more effort into this hospital model. It also provides laboratory services to drug companies for their clinical trials.
Burning Rock recorded revenue of US$77.2 million in 2025, and its gross profit margin was 74.7%. Its early detection test, OverC, received Breakthrough Device Designation from both the FDA and China's drug regulator, the NMPA, in 2023, and it has signed contracts with a small number of pilot hospitals to sell it. The company runs its business in China through a variable interest entity, or VIE: a Chinese company it controls by contract rather than by owning it, because Chinese rules bar foreign investors from genomic diagnosis.
Its biggest risks, as it describes them
- It has a history of net losses and may not reach or keep profitability.
- Hospitals and doctors may not keep using its therapy selection tests, and revenue from partner hospitals can swing with their budgets.
- It may fail to develop and sell its early cancer detection and residual disease tests on time, or at all.
- It relies on a small number of suppliers for some laboratory equipment and supplies.
- It runs its business through contracts with a VIE in China, which may not give the same control as owning it and may not be enforceable under Chinese law.
Income statement
Burning Rock Biotech lost money in fiscal 2025: a net loss of CN¥55 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,495 | 906 | 615 | 520 | 478 |
| Debt incl. finance leases | 2 | 0 | 0 | 0 | 2 |
| Net debt (negative means net cash) | −1,493 | −906 | −615 | −520 | −477 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −518.9x | −1,117.9x | — | — | −1,828.2x |
| Current ratio | 4.9x | 3.1x | 3.4x | 2.9x | 3.0x |
| Quick ratio | 4.6x | 2.7x | 3.1x | 2.7x | 2.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −53.7% | −23.0% | −1.6% |
| Altman Z'' | −9.52 | −12.40 | −11.46 |
| Accruals ratio | −30.3% | −26.4% | −3.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | — | — | — |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Burning Rock Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Burning Rock Biotech | FY25 | 4.6% | −10.2% | −6.2% | — | — | — | |
| Veracyte | FY25 | 16.0% | 11.2% | 24.5% | 6.1% | −4.6x | 6 | Compare |
| Starling Oncology | FY25 | 27.8% | −7.2% | −5.5% | −75.7% | — | 3 | Compare |
| Concord Medical Services | FY25 | 19.9% | −56.8% | −56.1% | −4.1% | — | 6 | Compare |
| GeneDx | FY25 | 40.0% | −3.1% | 3.3% | −5.3% | — | 6 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 209 | 382 | 430 | 508 | 563 | 537 | 516 | 540 |
| Revenue growth | — | 82.7% | 12.6% | 18.1% | 10.9% | −4.6% | −4.0% | 4.6% |
| Gross profit | 135 | 273 | 314 | 364 | 380 | 363 | 362 | 403 |
| Research and development | 105 | 157 | 264 | 368 | 422 | 347 | 232 | 166 |
| Operating income | −161 | −169 | −412 | −797 | −980 | −669 | −358 | −55 |
| Net income | −178 | −169 | −407 | −797 | −971 | −654 | −347 | −55 |
| Diluted EPS (CNY) | −10.38 | −14.23 | 0.00 | 0.00 | — | — | — | — |
| Diluted shares (millions) | 22 | 24 | 0 | 0 | — | — | — | — |
| Cash flow | ||||||||
| Cash from operations | −149 | −228 | −74 | −478 | −457 | −256 | −92 | −28 |
| Capital expenditure | 23 | 43 | 60 | 204 | 62 | 8 | 5 | 5 |
| Free cash flow | −172 | −271 | −134 | −682 | −519 | −264 | −98 | −34 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 23 | 173 | 282 | 327 | 261 | 156 | 14 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 93 | 408 | 2,257 | 1,495 | 906 | 615 | 520 | 478 |
| Debt incl. finance leases | — | 21 | 7 | 2 | 0 | 0 | 0 | 2 |
| Total assets | — | 848 | 2,663 | 2,279 | 1,588 | 1,040 | 885 | 820 |
| Total liabilities | — | 212 | 242 | 433 | 429 | 272 | 304 | 285 |
| Shareholders' equity | −604 | −892 | 2,421 | 1,845 | 1,158 | 768 | 581 | 535 |
| Margins and ratios | ||||||||
| Gross margin | 64.7% | 71.6% | 73.0% | 71.7% | 67.5% | 67.6% | 70.3% | 74.7% |
| Operating margin | −77.3% | −44.3% | −95.9% | −156.9% | −174.1% | −124.5% | −69.3% | −10.2% |
| Net margin | −85.0% | −44.3% | −94.7% | −156.9% | −172.4% | −121.6% | −67.2% | −10.3% |
| Free cash flow margin | −82.3% | −71.0% | −31.1% | −134.3% | −92.1% | −49.1% | −18.9% | −6.2% |
| Rule of 40 (growth + FCF margin) | — | 11.7% | −18.5% | −116.2% | −81.2% | −53.7% | −23.0% | −1.6% |
| Return on capital | — | — | — | −240.6% | −255.8% | −260.3% | −263.6% | — |
| Return on equity | — | — | −53.2% | −37.4% | −64.7% | −67.8% | −51.4% | −9.9% |
| Return on assets | — | — | −23.2% | −32.2% | −50.2% | −49.8% | −36.0% | −6.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |